PROMISING BREAKTHROUGH IN MENINGOCOCCAL VACCINE DEVELOPMENT BY IBG RESEARCHERS
A new generation vaccine with broader protective capacity at a low cost could be produced, providing affordable protection in global health.
A pioneering study, conducted by researchers from Izmir Biomedicine and Genome Center, Bilkent University, and Hacettepe University in Turkey, and supported by TUBITAK 1004 Program has unveiled a significant advancement in vaccine development against invasive meningococcal disease (IMD). The study, titled "Immunogenicity and Protective Capacity of CpG ODN Adjuvanted Alum Adsorbed Bivalent Meningococcal Outer Membrane Vesicle Vaccine," published recently in the International Immunology Journal presents a promising path towards affordable and broadly effective protection against meningococcal serogroups A, B, W, X, and Y.
Led by Prof. Dr. Ihsan Gursel, the research team aimed to address the urgent need for improved meningococcal vaccines, particularly in regions where IMD remains a significant public health concern.